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Abstract
Background—Curcumin (diferulolylmethane) has been shown to have a protective role in 
mouse models of inflammatory bowel diseases (IBD) and to reduce the relapse rate in human 
ulcerative colitis (UC), thus making it a potentially viable supportive treatment option. 
Trinitrobenzene sulfonic acid (TNBS) colitis in NKT-deficient SJL/J mice has been described as 
Th1-mediated inflammation, whereas BALB/c mice are believed to exhibit a mixed Th1/Th2 
response.
Methods—We therefore investigated the effect of dietary curcumin in colitis induced in these 2 
strains.
Results—In the BALB/c mice, curcumin significantly increased survival, prevented weight loss, 
and normalized disease activity. In the SJL/J mice, curcumin demonstrated no protective effects. 
Genomewide microarray analysis of colonic gene expression was employed to define the 
differential effect of curcumin in these 2 strains. This analysis not only confirmed the disparate 
responses of the 2 strains to curcumin but also indicated different responses to TNBS. Curcumin 
inhibited proliferation of splenocytes from naive BALB/c mice but not SJL/J mice when 
nonspecifically stimulated in vitro with concanavalin A (ConA). Proliferation of CD4+ 
splenocytes was inhibited in both strains, albeit with about a 2-fold higher IC50 in SJL/J mice. 
Secretion of IL-4 and IL-5 by CD4+ lymphocytes of BALB/c mice but not SJL/J mice was 
significantly augmented by ConA and reduced to control levels by curcumin.
Conclusions—The efficacy of dietary curcumin in TNBS colitis varies in BALB/c and SJL/J 
mouse strains. Although the exact mechanism underlying these differences is unclear, the results 
Copyright © 2008 Crohn’s & Colitis Foundation of America, Inc.
Reprints: P. R. Kiela, Department of Pediatrics, Steele Children’s Research Center, University of Arizona Health Sciences Center, 
1501 N. Campbell Ave., Tucson, AZ 85724 (pkiela@peds.arizona.edu).




Inflamm Bowel Dis. Author manuscript; available in PMC 2015 May 11.
Published in final edited form as:













suggest that the therapeutic value of dietary curcumin may differ depending on the nature of 
immune dysregulation in IBD.
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Idiopathic inflammatory bowel diseases [IBD; Crohn’s disease (CD) and ulcerative colitis 
(UC)] are defined as autoimmune diseases implicated in aberrant and persistent 
inflammation of the bowel because of an excessive effector response or an insufficient 
regulatory response to commensal bacterial flora.1 Both environmental factors and genetic 
predisposition have been implicated in the pathogenesis of CD and UC, although their 
precise contributions remain incompletely understood.1–4 Although both CD and UC share a 
common basis in immune hyperresponsiveness to mucosal antigens, the 2 diseases vary 
considerably. Crohn’s disease is associated with a Th1/Th17 cell–mediated response 
mediated by IL-12 and IL-23, with concomitant increased production of IFNγ, IL-2, IL-18, 
and IL-17,1,5–7 whereas ulcerative colitis is associated with an atypical Th2 response 
characterized by NKT secretion of IL-13 accompanied by increased production of IL-4 and 
IL-5.1,8
Both in human IBD and in animal models of the disease, the development and persistency of 
inflammation depend partially on the activation and nuclear translocation of the NFκB 
complex. Although with somewhat different mechanisms, NFκB regulates transcription of 
both Th1/Th17-associated cytokines like IL-12 and IL-239–12 and the Th2 cytokines IL-4 
and IL-13,13,14 making NFκB an attractive therapeutic target in both CD and UC. In fact, 
decoy oligonucleotides containing NFκB-binding sites were proven effective in both the 
prevention and treatment of murine Th1 and Th2 models of hapten-induced colitis.15 
Curcumin (diferulolylmethane) is also an emerging candidate drug targeting, among other 
pathways, the signaling events leading to NFκB activity.16 The effects of curcumin on the 
immune response (both innate and adaptive) has been a subject of much attention in the past 
decade.17 Curcumin has been identified as the most active constituent of turmeric and has 
been described as an anti-inflammatory, antioxidant, proapoptotic, and antiproliferative 
compound.18–21 In addition, this compound regulates the activity of several enzymes via 
direct interaction or can modulate gene transcription through the inhibition of transcription 
factors and signaling pathways.22 Curcumin has been shown to play a protective role in 
chemically induced mouse models of IBD23–26 and to reduce the relapse rate in human 
UC.27
Colitis can be efficiently induced in mice using a rectally administered haptenizing agent, 
trinitrobenzene sulfonic acid (TNBS) in 50% ethanol, with the nature of the immune 
response to TNBS depending on the genetic background of the mice used. In BALB/c mice, 
TNBS colitis develops independently of IFNγ, with prominent Th2 responses in colonic 
patches and lesions.28 Although Th1 response and IFNγ has been implicated in the early 
deaths of TNBS-treated BALB/c mice, in later stages of the disease in this strain, expression 
of IFNγ mRNA in CD4+ cells is undetectable, whereas morphological changes in the 
colonic mucosa are reminiscent of those observed in ulcerative colitis.28 In contrast, TNBS-
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induced colitis in SJL/J mice is mediated by Th1-type T cells and is associated with high 
production of IL-12 and IFNγ. This response may be attributed to a susceptibility locus on 
chromosome 11 of SJL/J mice, associated with increased IL-12 responses to parenteral 
injection of LPS.29 The importance of IL-12 and/or IL-23 was demonstrated by the efficacy 
of a single injection of anti-p40 antibody in preventing colitis.30 Colitis in SJL/J mice can 
also be prevented by the administration of anti-CD40, blocking CD40–CD40L interactions, 
which are crucial in Th1-mediated inflammation.31,32 The key role of TNFα in TNBS colitis 
in the SJL/J strain also confirms the importance of the Th1 pathway because TNFα-deficient 
mice do not develop inflammation.33 The Th1-skewed response to TNBS in SJL/J mice is 
likely a result of a defect in NKT cells that have been implicated in IL-13 production and 
associated with an atypical Th2 response in ulcerative colitis.8 SJL/J mice have drastically 
reduced the number of B220−/CD1d tetramer+ NKT cells34 with defective T-cell-receptor-
induced IL-4 production and absence of T cells expressing NK1.1.35
In this study, we investigated the effect of dietary curcumin in a concentration previously 
demonstrated as effective in BALB/c mice (2%)25 in the 2 strains of mice: SJL/J and 
BALB/c. This model of hapten-induced colitis allows the study of the initial event in the 
development of mucosal inflammation, associating the response to specific antigen (in the 
presence of ethanol) and the mucosal immune response leading to colonic inflammation. 
Our results indicate that in BALB/c mice, which exhibit a mixed Th1/Th2 response, dietary 
curcumin significantly increases survival, protects from weight loss, and normalizes the 
indices of the disease, while remaining ineffective in Th1-skewed SJL/J mice. Using a 
genomewide microarray analysis of colonic gene expression, we identified a differential 
pattern of genes regulated by dietary curcumin in these 2 mouse strains. Moreover, in vitro, 
curcumin inhibits concanavalin A (ConA)–induced proliferation of splenocytes from naive 
BALB/c mice but not SJL/J mice. The curcumin IC for CD4+ 50 T-cell proliferation was 2-
fold higher in SJL/J mice than in BALB/c mice. Our results therefore provide a side-by-side 
comparison of the effectiveness of curcumin in 2 immunologically distinct models of 
chemically induced colitis and may suggest potential differences in the usefulness of this 
compound in Crohn’s disease and ulcerative colitis.
MATERIALS AND METHODS
Curcumin
Curcumin was isolated from commercially obtained turmeric powder, Curcuma longa L., 
Zingiberaceae, according to the unpublished method of Timmermann et al (Higuchi 
Biosciences Center, University of Kansas, Lawrence, Kan.; patent pending). Briefly, the 
method consists of 3 steps, 2 solvent extraction steps and a chromatography step, employing 
commonly used water-miscible and -immiscible solvents in industrial-scale processes. 
Quality control was performed by high-performance liquid chromatography (HPLC) using 
an Agilent system comprising an Agilent 1100 pump, a thermostated column compartment, 
a nonthermostated autosampler and diode array detector, a Luna C18 column (Phenomenex), 
and a guard column (SecurityGuard AJO-4287; Phenomenex; Torrance, CA) with mobile 
phases A (500 μL of acetic acid/L of Nanopure water) and B (500 μL of acetic acid/L of 
acetonitrile). Detection was performed at 425 and 250 nm with ChemStation for LC 3D, 
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Rev. A. 09.03 (1417) for data acquisition (Agilent). Mass spectrometry (MS) analysis was 
performed with an Agilent 1100 HPLC system in tandem with an Agilent LC-MSD-Trap-SL 
ion trap mass spectrometer using MSD Trap Control 5.0 with LC/MSD Trap software 4.1 by 
Bruker Daltonic GmbH for data acquisition.
Animals and Diets
Six-week-old male BALB/c and SJL/J mice (18–21 g B.W.) were obtained from Harlan 
Laboratories (Indianapolis, Ind.) and maintained in the animal facility at the University of 
Arizona, College of Medicine. Mice were fed a control diet (NIH-31; Harlan Teklad, 
Madison, Wis.) or a diet supplemented with 2% curcumin. Diets were prepared daily by 
mixing powdered food with curcumin (2% final content) in a mortar until homogeneity was 
observed. Water (0.65 mL/g diet) with microwave-melted agar (0.1% final content in the 
diet) was subsequently added and mixed well, and the diet was divided into daily portions 
based on an estimated consumption of 5 g of dry matter per mouse per day. The stability of 
curcumin in the diet was evaluated by HPLC. Aliquots (3× 200 mg) of the diet were 
removed at times 0, 2.5, 5, 9, and 24 hours and immediately extracted with 5 mL of a 1:1 
mixture of dichloromethane and methanol. Samples were injected into a Luna C18 (2) 
column with a SecurityGuard AJO-4287 guard column (both from Phenomenex) and 
analyzed in an Agilent 1100 system with a diode array detector at 425 and 250 nm. The area 
under the curve (AUC) of the curcumin peak was calculated, averaged, and plotted (Fig. 1). 
Feeding the 2 diets began 2 days prior to the administration of TNBS and continued for 7 
days, until sacrifice. Mice were administered TNBS intrarectally (2 mg/mouse in 50% 
ethanol) or phosphate-buffered saline as a control in a total volume of 100 μL (3.5 cm from 
the anal verge) using a 1-mL syringe fitted with a polyethylene cannula. Mice were then 
kept in a vertical position for 30 seconds before being returned to their cages. Body weight 
and mortality were monitored daily. Three experimental groups were used in both mouse 
strains: control diet/control enema, control diet/TNBS enema, and 2% curcumin diet/TNBS 
enema. An additional group of BALB/c mice fed the curcumin-supplemented diet for 9 days 
was included to study the effects of curcumin alone on colonic gene expression.
Histological Evaluation
Proximal and distal colons from BALB/c and SJL/J mice were harvested and fixed in 10% 
neutral buffered formalin (Fisher Scientific, Tustin Calif.) and paraffin embedded. Five-
micrometer tissue cuts were stained with hematoxylin and eosin (H&E) for light 
microscopic examination. A veterinary pathologist blinded to the study design graded the 
sections by scoring them on a scale from 0 to 5. The scoring table was based on the criteria 
degree of lamina propria mononuclear cell infiltration, crypt hyperplasia, and architectural 
distortion, as previously described.36 Proximal and distal colons were scored separately, and 
the sum of the 2 scores for individual mice was used for statistical analysis. Images from 
H&E-stained slides were obtained for documentation and presentation using a Zeiss 
Axioplan microscope fitted with a Nikon DS-Fi1 digital camera.
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Microarray Analysis of Colonic Gene Expression
Colonic tissues (whole colon) from 9 mice randomly selected from each treatment group 
were pooled (3 per sample), and RNA was purified with TRIzol reagent (Invitrogen, 
Carlsbad, Calif.) to yield 3 pooled samples per group. Total RNA (100 μg) was cleaned up 
with an RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. RNA was 
evaluated by denaturing agarose gel electrophoresis, the 28S/18S rRNA ratio was calculated, 
and concentrations were adjusted according to densitometric analysis of the 18S rRNA. 
Only high-quality RNA, as evaluated by the intactness of the ribosomal bands, was used for 
gene chip analysis. RNA samples were subsequently processed to yield biotinylated cRNA 
for hybridization to Affymetrix Mouse Gene Array Expression Set 430 (Affymetrix, Santa 
Clara, Calif.) according to the manufacturer’s recommendations (Affymetrix; Expression 
Analysis Technical Manual) using reagents provided by Affymetrix [Gene Chip Sample 
Cleanup Module, T7-oligo(dT) primer, GeneChip IVT Labeling Kit] or Invitrogen (dNTP 
mix, SuperScript II Reverse Transcriptase, E. coli DNA ligase, E. coli DNA polymerase I, 
E. coli RNase H). Fragmented cRNA was mixed with control oligonucleotide B2 
(Affymetrix), eukaryotic hybridization controls (Affymetrix), herring sperm DNA 
(Invitrogen), bovine serum albumin (Invitrogen), 2× hybridization buffer, and RNAse-free 
water. This hybridization cocktail was then applied to GeneChip Mouse Expression Set 430 
(Affymetrix) and hybridized at 45°C for 16 hours while spinning at 53 rpm. The GeneChip 
Mouse Expression Set 430 provides comprehensive coverage of the transcribed mouse 
genome on a 2-array set with about 45,000 probe sets to analyze the expression of more than 
39,000 transcripts and variants from more than 34,000 well-characterized mouse genes. 
Chips were immediately washed and stained with the GeneChip Fluidics Station 400 
(Affymetrix). SAPE and antibody solutions were prepared according to the manufacturer’s 
recommendations (Affymetrix), and chips were washed and stained utilizing the EukGE-
WS2v5 fluidics protocol. After the chips had been washed and stained, they were scanned 
with the GeneChip Scanner 3000 (Affymetrix). Obtained data were subsequently exported 
for analysis to GeneSpring v.7.0 (Silicon Genetics, Redwood City, Calif.). Stringent 
empirical and statistical analyses were employed to compare gene expression profiles 
between mice in different treatment groups, with a cross-gene error model based on 
replicates. Normalized data (per gene, per chip, and per sample, with healthy controls 
serving as a reference point) were serially filtered in the following order: selected genes 
flagged as present or marginal in at least 3 of 9 samples; selected genes up- or down-
regulated at least 1.5-fold with P ≤ 0.05 (control versus TNBS, both on control diet; Student 
t test); and selected genes with P ≤ 0.5 according to ANOVA (with all 3 treatment groups) 
and significantly different between TNBS-treated mice on control or curcumin-
supplemented diet [by Student-Newman-Keuls (SNK) post hoc test].
Real-time RT-PCR
Expression of selected genes based on the outcome of microarray analysis was 
independently analyzed by real-time RT-PCR. 200 ng of total RNA was reverse-transcribed 
using an iScript kit (Bio-Rad, Hercules, Calif.), and 10% of the RT reaction was used for 
real-time PCR analysis using TaqMan technology and commercially available primers from 
Applied Biosystems (Foster City, Calif.) with iQSupermix (Bio-Rad) and the iCycler optical 
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PCR cycler (Bio-Rad). The resulting data were analyzed using the comparative Ct method 
as a means of relative quantitation of gene expression, normalized to an endogenous 
reference (TATA box–binding protein) and relative to a calibrator (normalized Ct value 
obtained from control mice), and expressed as 2−ΔΔCt, as described by the manufacturer 
(Applied Biosystems).
Lymphoid Cell Preparation and Stimulation by Concanavalin A
Spleens of naive BALB/c or SJL/J mice were removed, and single-cell suspensions were 
prepared by gentle teasing. Cells were washed and resuspended in complete medium (RPMI 
1640, Invitrogen, Carlsbad, Calif.) supplemented with 10% heat-inactivated fetal calf serum 
(Gemini Bio-products, West Sacramento, Calif.), 2 mM L-glutamine, 50 mg/mL of 
gentamicin (Sigma, St. Louis, Mo.), 100 U/mL penicillin, and 100 mg/mL streptomycin 
(Invitrogen, Carlsbad, Calif.). Red blood cells were lysed in a hypotonic buffer (BD 
Biosciences, San Jose, Calif.) and washed twice in a complete medium. CD4+ cells were 
purified from the total population of splenocytes using magnetic separation and an 
autoMACS instrument according to manufacturer’s instructions (Miltenyi Biotec, Auburn, 
Calif.). CD4+ T cells were selected using the DepletS program. Flow cytometry analysis 
(FACSCalibur; BD, Franklin Lakes, NJ) indicated that more than 95% of the selected cells 
coexpressed CD3 and CD4. Cells were cultured at a concentration of 106 cells/mL in 96-
well flat-bottomed plates (BD Bioscience). Splenocytes or CD4+ T cells were 
nonspecifically stimulated in vitro with concanavalin A (Sigma) at a concentration of 5 
μg/mL and treated with DMSO or increasing concentrations of curcumin (from 0.5 to 5 μM) 
for 72 hours. In a separate series of experiments, cell culture supernatants were collected and 
stored at −80°C for cytokine analysis. For the proliferation assay, cells were pulsed with 1 
μCi/well [3H]-thymidine (MP Biomaterial, Costa Mesa, Calif.) after 56 hours of culture and 
incubated for an additional 16 hours. Cells were then harvested using a 96-well Packard cell 
harvester, and radioactivity was measured on a Packard Beta Counter (Packard Biosciences, 
Meriden, Conn.). The curcumin IC50 was calculated for BALB/c and SJL/J CD4+ T cells or 
splenocytes stimulated with concanavalin A and treated with increasing concentrations of 
curcumin—0.5, 1, 1.25, 2.5, and 5 μM—according to the [3H]-thymidine measurements.
Statistical Analysis
Statistical significance was determined by the Student t test or analysis of variance 
(ANOVA) followed by the Fisher PLSD test using the StatView software package version 
4.53 (SAS Institute, Cary, NC). Data are expressed as mean ± standard error of the mean. 
Microarray analysis was performed using GeneSpring GX 7.3 (Agilent Technologies, Santa 
Clara, Calif.) utilizing both empirical and statistical tools (t test, 1-way ANOVA, Student-
Newman-Keuls post hoc test) in the software package.
Ethical Considerations
All methods used in this study were reviewed and approved by the Institutional Animal Care 
and Use Committee of the University of Arizona.
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Purity and Stability of Curcumin
The isolated curcumin was more than 97% pure as judged by HPLC (Fig. 1A) and 
completely devoid of coextracted curcuminoids, demethoxycurcumin and bis-
demethoxycurcumin, commonly detected as contaminants in commercial curcumin. Its 
melting point, elemental analysis, and molecular weight by MS and H-NMR were in accord 
with the structure (Fig. 1B). Organic extraction and LC-MS analysis indicated no apparent 
degradation of dietary curcumin within 24 hours (Fig. 1C).
Curcumin Significantly Increased Survival and Protected from Body Weight Loss in 
BALB/c But Not SJL/J Mice
Both strains of mice responded to TNBS treatment with significant mortality, which reached 
35% in BALB/c mice and 50% in SJL/J mice (Fig. 2A). This was accompanied by body 
weight loss, as great as 27% and 28% of body weight in the BALB/c and SJL/J strains, 
respectively (Fig. 2B). Two percent dietary curcumin administered in a preventive mode in 
settings similar to those described by Sugimoto et al25 offered significant protection against 
TNBS-induced mortality in BALB/c mice but not SJL/J mice (Fig. 2A). Similarly, curcumin 
prevented significant body weight loss in TNBS-treated BALB/c mice, whereas body weight 
loss and recovery of SJL/J mice was not improved by the curcumin-supplemented diet (Fig. 
2B).
Curcumin Improves Colonic Histology of BALB/c Mice But Not SJL/J Mice
Colon sections were interpreted semiquantitatively in a blinded manner by a veterinary 
pathologist according to previously published critieria,36 taking into account lymphocytic 
and neutrophilic infiltration, crypt hyperplasia, mucosal ulcerations, focal or multifocal 
transmural necrosis, penetration of the colonic wall, and exuberant subacute peritonitis 
encompassing the adjacent pancreatic tissue. The final histological score, depicted in Figure 
3G, is the sum of the scores from the proximal and distal segments of the mouse colon. 
Consistent with the effects on mortality and body weight loss, curcumin treatment resulted 
in statistically significant improvement in the histology score of BALB/c mice but not SJL/J 
mice (Fig. 3).
Microarray Analysis of Colonic Gene Expression Revealed TNBS Colitis Alters Expression 
of Distinct Sets of Genes in BALB/c and SJL/J Mice
Genomewide microarray analysis (MOE430 set; Affymetrix) of colonic gene expression in 
BALB/c and SJL/J mice was performed using GeneSpring GX 7.3.1 software (Agilent). 
Genes/probe sets were selected as follows: (1) present or marginal in 2 of 6 samples (3 
biological repetitions per treatment per strain), (2) expression increased or decreased at least 
1.5-fold, (3) t test showing P < 0.05 between control and TNBS-treated mice. In the BALB/c 
mice, a total of 965 genes/probe sets were differentially expressed, whereas in the SJL/J 
mice, expression of 800 genes/probe sets was altered. The Venn diagram depicted in Figure 
4 indicates a relatively small set of genes common to both strains, which were significantly 
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altered by TNBS colitis, thus indicating the 2 strains had a significantly different response to 
a common haptenizing agent (TNBS).
Colonic Gene Expression Profiles in BALB/c and SJL/J Mice Confirmed Differential 
Response to Curcumin
The genes/probe sets identified in Figure 4 as induced or repressed at least 1.5-fold (P < 
0.05) in TNBS colitis were analyzed by 1-way ANOVA followed by the Student-Newman-
Keuls post hoc (SNK) test for all 3 groups of mice (control, TNBS, TNBS+curcumin). 
ANOVA identified 469 genes in the BALB/c mice and 211 genes in the SJL/J mice. Of 
these, 428 genes were significantly different (normalized) in the BALB/c mice according to 
the SNK test (91.3%), whereas only 41 genes/probe sets were different in the SJL/J mice 
(19.4%), shown in Figure 5A. Moreover, the expression pattern of genes/probe sets 
identified in the BALB/c mice by ANOVA and the SNK test (Fig. 5A) was very different in 
the SJL/J mice. A vast majority of the genes whose expression was normalized by curcumin 
in the BALB/c mice (Fig. 5B) were not affected in the SJL/J mice (Fig. 5C). Further analysis 
of the differential response to curcumin among the 2 mouse strains focused on genes 
affected by TNBS colitis and normalized by curcumin in BALB/c but not SJL/J mice. To 
this end, we identified a subset of 116 genes/probe sets whose expression was normalized by 
curcumin treatment in BALB/c mice (as determined by ANOVA and post hoc testing) but 
were not significantly altered in SJL/J mice (P > 0.05 between TNBS and TNBS/curcumin 
by SNK test). To gain insight into the functional relevance of the identified genes that were 
targets of strain-specific effects of curcumin, this list of genes/probe sets was analyzed with 
the Functional Annotation Tool and the Database for Annotation, Visualization, and 
Integrated Discovery (DAVID), developed and maintained by the National Institute of 
Allergy and Infectious Diseases (http://david.abcc.ncifcrf.gov/).37 Biological process gene 
ontological analysis grouped these 116 genes/probe sets into several functional categories (P 
value ranging from 0.05 to 3.6 × 10−09), consistent with an inflammatory response (Fig. 6). 
On close inspection, this list consisted of 97 nonredundant, well-characterized genes, a large 
number of which are known to be involved in the pathogenesis of inflammatory bowel 
diseases, with genes involved in the acute-phase response, cell adhesion, and the response to 
a biotic stimulus particularly overrepresented. Table 1 depicts genes selected from among 
the 97 with expression data demonstrating a differential effect of dietary curcumin in the 
BALB/c and SJL/J mice.
TNFα is a prominent player in Th1 responses and is a well-established target of biological 
therapies, particularly in Crohn’s disease. In our studies, expression of TNFα was too low to 
be reliably compared by hybridization-based microarray analysis. However, real-time PCR 
analysis demonstrated that the TNBS-treated SJL/J mice had significantly higher expression 
of TNFα than did the BALB/c mice, and dietary curcumin effectively reduced expression in 
the latter strain while remaining ineffective in the SJL/J mice (Fig. 7).
Identification of Overrepresented Transcription Factor–Binding Sites in Curcumin-
Responsive Genes
To gain further insight into the transcriptional effects of curcumin in BALB/c mice, we used 
the set of 116 genes/probe identified as responding to curcumin treatment in BALB/c mice 
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but not SJL/J mice to perform an analysis of transcription factor–binding sites (TFBSs) in 
the known gene promoters. To accomplish this, we utilized the oPOSSUM tool, recently 
developed by Ho Sui et al (http://www.cisreg.ca/oPOSSUM/).38 The oPOSSUM algorithm 
identifies overrepresented, predicted TFBSs in sets of human and mouse genes as compared 
to a defined genomic region of 1000 randomly selected background genes. Our analysis 
included 1000 bp upstream of the known or predicted transcription start site. From the 
submitted 116 genes/probe sets, 71 were included in the analysis. From among the 
overrepresented TFBSs, those previously demonstrated as targets of curcumin stood out 
(Fos/AP-1, NFκB, and PPARγ; Table 2). Although caution should be used interpreting 
TFBSs found overrepresented based on smaller background gene hits, some may represent 
true information about new, previously undescribed nuclear targets of curcumin, such as 
SRY/Sox5/Sox9 (members of the high-mobility group–box family of DNA-binding 
proteins), or homeobox transcription factors, generally implicated in regulating tissue-
specific gene expression essential for tissue differentiation (Hox11, Prrx2, Nkx2-5, TCF1; 
Table 2).
Limited Effects of Dietary Curcumin on Colonic Transcriptome in Naive BALB/c Mice
Curcumin is most effective when administered in a preventive mode prior to induction of 
colitis.25 To test whether curcumin acts to modify baseline gene expression or acts solely to 
prevent changes in colonic gene expression in response to an inflammatory insult, we 
analyzed the gene expression profile in the responsive mouse strain (BALB/c) to 2% dietary 
curcumin administered alone for the duration of the study (9 days). We observed very 
limited effects of the compound on the colonic transcriptome, consistent with the reported 
lack of toxic effects in rodents and humans. Microarray analysis performed in an analogous 
way to that already described identified only 6 genes significantly (≥1.5-fold change; P < 
0.05, t test) affected by dietary curcumin. These include CHOP10/Ddit3 (2.47-fold induction 
by curcumin), glutathione S-transferase α2 (1.92-fold induction), HSPA5 (2.55-fold 
induction), coiled-coil domain containing 116 (Ccdc116; 2.11-fold induction), aldo-keto 
reductase family 1, member B (AKR1B1; 1.89-fold increase), and Wiskott-Aldrich 
syndrome-like gene (WASL; 1.89-fold increase).
Curcumin Differentially Modulates Mitogen-Induced BALB/c and SJL/J Splenocyte and 
CD4+ T-Cell Proliferation In Vitro
To help explain the strain-specific in vivo response to curcumin, we also evaluated the 
proliferative response of total splenocytes or purified CD4+ T cells obtained from BALB/c 
or SJL/J mice. Total splenocytes and magnetically selected CD4+ T cells were stimulated by 
a nonspecific mitogenic agent concanavalin A (ConA; 5 μM)) and cotreated with increasing 
concentrations of curcumin. The concentrations used were verified as noncytotoxic by the 
Trypan blue exclusion assay and by adenylate kinase release (ToxiLight Non-destructive 
Cytotoxicity Assay, Cambrex, NJ; data not shown). As anticipated, SJL/J mice generally 
had a much lower proliferative response to ConA than the BALB/c strain (Fig. 8). Curcumin 
effectively and dose-dependently inhibited proliferation of the BALB/c-derived splenocytes 
remaining (Fig. 8A) without a significant effect on splenocytes obtained from the SJL/J 
mice (Fig. 8B). Although the strain-related difference in the effects of curcumin on the 
proliferation of CD4+ lymphocytes was less dramatic than with total splenocytes, the IC50 
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calculated based on 5 independent experiments was somewhat higher in SJL/J mice than in 
BALB/c mice (4.1 vs. 2.5 μM, respectively; P < 0.05). In response to ConA stimulation, 
secretion of 2 key Th2 cytokines, IL-4 and IL-5, was significantly increased in the BALB/c-
derived splenocytes (9-fold and 2.4-fold, respectively) and was significantly reduced by 5 
μM curcumin, whereas both cytokines remained unaffected by ConA or curcumin in 
splenocytes obtained from SJL/J mice.
DISCUSSION
Curcumin has a broad spectrum of biological actions including chemotherapeutic, anti-
inflammatory, antiangiogenic, and antioxidant effects. These were reviewed in depth in a 
recent monograph by Aggarwal, Surh, and Shishodia.39 The pleiotropic effects of curcumin 
could be attributed in part to the inhibition of NFκB, a finding that prompted several recent 
studies, which demonstrated the effectiveness of curcumin in chemically induced models of 
colitis.23–26 Moreover, curcumin has been demonstrated to be a promising, safe medication 
for maintaining remission in patients with quiescent ulcerative colits (UC).27 Clinical studies 
of potentially therapeutic or preventive effects of curcumin in Crohn’s disease are generally 
lacking, with the exception of a limited study by Holt et al.40 There are considerable 
differences in the pathogenesis, clinical manifestations, and outcomes of CD and UC, 
although generally there are no medications tailored specifically for either disorder.
Dichotomizing IBD as Th1 driven (Crohn’s disease) and Th2 or atypical Th2 response 
(ulcerative colitis) may be oversimplified based on current knowledge of IBD pathogenesis. 
It is even more contentious whether the TNBS colitis model can truly represent CD or UC, 
or simply an acute inflammation, a rather nonspecific component of IBD. Keeping in mind 
this and the known immunological differences between BALB/c and SJL/J mice described 
in the introduction, it is remarkable to see the striking differences in colonic gene expression 
pattern in response to the same haptenizing agent in BALB/c and SJL/J mice, 2 strains 
considered susceptible to TNBS-induced colitis.41 Although precise analysis of the 
differences in transcriptional response to TNBS in BALB/c and SJL/J mice is beyond the 
scope and limitations of this article, it is likely that this vastly different response to a 
proinflammatory insult also underlies the described differential effect of dietary curcumin. 
Despite multiple reports indicating the protective effects of curcumin in chemically induced 
colitis,23–26 we have repeatedly demonstrated lack of any positive effects of the compound 
in SJL/J mice in mortality, body weight loss, colonic histology, or colonic gene expression 
pattern. At the same time, BALB/c mice were consistently protected when administered 
curcumin in a preventive mode.
It remains unclear whether the protective effects of curcumin are dependent on polarization 
of T-cell responses in these 2 strains. Real-time RT-PCR analysis of colonic TNFα 
expression seems to indicate that the induction of the cytokine expression and differential 
effects of curcumin in BALB/c and SJL/J mice may be one factor determining the overall 
responsiveness to this drug. On the other hand, there are reports of in vitro studies that 
demonstrated curcumin-mediated inhibition of the Th1 activation pathway and skewing of 
the inflammatory response from Th1 to Th2. Kang et al showed that curcumin inhibited 
IL-12 production by LPS-induced macrophages, reduced their ability to induce IFN-γ, and 
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increased their ability to induce IL-4 in antigen-primed CD4+ T cells.42 More recently, Kim 
et al demonstrated that curcumin-treated bone marrow–derived dendritic cells (DCs) also 
exhibited impaired IL-12, IL-1β, IL-6, and TNFα expression in response to LPS.19 In 
addition, curcumin-treated DCs showed impaired induction of Th1 responses.19 In vivo, 
curcumin was also shown to inhibit the Th1 cytokine profile,42,43 although in both cases this 
was accomplished with curcumin administered intraparenterally. Therefore, these studies 
were not conducted in settings achievable in human patients, where curcumin can only be 
administered orally and for whom no suitable means of parenteral administration have been 
described or approved by the Food and Drug Administration. It is likely that limited 
bioavailability and rapid metabolism of curcumin to compounds of unknown anti-
inflammatory activity may both be factors in the ultimate effectiveness of curcumin in 
different forms of colonic inflammation. Also, it is not inconceivable that the observed more 
rapid onset of colitis in SJL/J mice was a factor in the overall efficacy of curcumin. 
Although little is known about the absorptive mechanisms of curcumin and the role of 
intestinal mucus, differences in mucus secretion, a potential diffusional barrier, particularly 
for lipophilic drugs, could contribute to differences in curcumin accessibility to the colonic 
epithelium.
Differential genomewide analysis of colonic gene expression clearly underscores the 
difference in clinical response to curcumin in the tested 2 strains of mice, with 91.3% of 
genes dysregulated by TNBS brought back to control levels in BALB/c mice and only 
19.4% of genes affected by curcumin in SJL/J mice (Fig. 5). Focusing further analysis on 
genes affected by curcumin specifically in BALB/c mice and not in SJL/J mice, we hoped to 
gain insight into curcumin’s mechanism of protection from colitis. This list, depicted in 
Table 1, consists of 97 nonredundant genes, many of them known to be involved in the 
pathogenesis of inflammatory bowel diseases, with a particularly well-represented group of 
genes involved in cell adhesion. These include the members of the immunoglobulin 
superfamily, ICAM1, and MADCAM1. Although microarray data for VCAM1 were 
somewhat inconsistent (with disparate results from 4 probe sets), real-time PCR analysis 
confirmed the same pattern of expression, with VCAM1 elevated 12.06-fold ± 4.4-fold in 
TNBS-treated BALB/c mice and reduced 2.23-fold ± 0.3-fold over control mice by feeding 
them a curcumin-supplemented diet. At the same time, elevated expression of VCAM1 in 
colitic SJL/J mice was not affected by curcumin (data not shown). The binding of VCAM1 
and MADCAM1 to their respective integrin ligands has been a target for drug development 
in recent years.44 Similarly, antisense therapy directed toward ICAM1 (Alicaforsen; ISIS 
2302) showed promising results in studies with CD, unremitting pouchitis, and UC 
patients.45 It is plausible that the protective effects of curcumin are a result of its lack of 
specificity and its targeting of multiple genes and signaling pathways. Down-regulation of 
adhesion molecule expression was accompanied by simultaneous inhibition of cytokine and 
chemokine expression (e.g., IL1β, MIP-2, IL-6). Also, TLR-4 signaling, known to be 
affected by curcumin at the NFκB signaling cascade level,16 inhibition of ligand-dependent 
and -independent TLR-4 dimerization,46 and direct binding to MD-2,47 may be further 
affected by the observed down-regulation of LPS-binding protein (Table 1) and CD14. The 
latter was significantly induced by TNBS colitis in both BALB/c and SJL/J mice but 
reduced by curcumin in the BALB/c strain only (also confirmed by real-time PCR; not 
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shown). CD14 was not included in the comparison presented in Table 1 because it did not 
pass the 1-way ANOVA test in SJL/J mice.
Microarray analysis of colonic gene expression in response to dietary curcumin in naive 
BALB/c mice showed very limited effects of the drug. This finding underscores the lack of 
apparent toxicity of curcumin and suggests it is unlikely that wide alterations of the colonic 
transcriptome set the stage for the attenuated response to TNBS in this mouse strain. Of the 
6 identified genes induced by curcumin, the role of 3 is unclear (GSTa2, AKR1B1, 
Ccdc116), though it is possible that the first 2 may be up-regulated in response to curcumin 
metabolism. Chop10/Ddit3 has been shown to be activated by ER stress48 and to act as an 
inhibitor of C/EBP DNA binding.49 Incidentally, the C/EBP binding site was found 
overrepresented in curcumin-regulated genes in BALB/c mice (Table 2). Induction of 
HSPA5, a member of the HSP70 family of heat shock proteins, may also be related to ER 
stress. This protein is believed to be a key element in sensing the folding capacity within the 
ER.50 Perhaps the most intriguing finding is the induction of the WASL (N-WASP) gene by 
curcumin. WASL is a ubiquitously expressed functional homologue of WASP (Wiskott-
Aldrich syndrome protein), with both playing key regulatory roles in cellular actin assembly 
and in integrating surface-receptor signals to the actin cytoskeleton. Most importantly, very 
recently WASP-deficient mice were described to develop Th2-like colitis.51 Although an 
intriguing concept, answering the questions of whether WASL plays a similar role in the 
development of colitis and whether its induction by curcumin is of importance in the overall 
anti-inflammatory effects of the compound remains largely speculative.
The important question that remains is why the same genes are differently affected by 
curcumin in these 2 strains. Unfortunately, microarray analysis does not provide enough 
information to answer it. Analysis of transcription factor (TF)–binding sites overrepresented 
in promoters of genes affected in BALB/c mice but not SJL/J mice (Table 2) returned a 
number of TFs consistent with current knowledge about the transcriptional effects of 
curcumin (NFκB family, AP-1, PPARγ), along with many others that have not yet been 
described as affected by curcumin. It remains to be elucidated whether they represent true 
targets of the compound and whether they play a role in the different responses to curcumin 
in BALB/c and SJL/J mice. Our in vitro observations also suggest that some of the 
differential effects of curcumin may stem from differences in the potency of the compound 
to inhibit splenocyte and CD4+ T-cell proliferation in these 2 strains. We have shown that 
the IC50 of curcumin was nearly 2-fold higher for SJL/J-derived CD4+ T cells, whereas 
ConA-induced proliferation of total SJL/J splenocytes was completely unaffected. In sharp 
contrast, mitogen-induced BALB/c splenocyte proliferation was greatly inhibited by low and 
noncytotoxic concentrations of curcumin (Fig. 8). Although the mechanism of these 
puzzling yet striking differences is unclear, it may also represent the basis for the selective 
efficacy of curcumin in the 2 tested mouse strains. It is also plausible that pharmacokinetic 
properties of curcumin or metabolic activity of enzymes involved in biotransformation of 
curcumin into potentially active or inactive metabolites varies among different mouse 
strains, although this has never been demonstrated.
Based on our results, it is tempting to speculate that dietary curcumin may be of different 
value for Crohn’s disease and ulcerative colitis. Although the usefulness of this compound 
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in maintaining remission in UC has been recently demonstrated,27 no well-designed trials 
with CD patients have been published. To support this hypothesis, our results would also 
have to be further verified in established immune models of Crohn’s disease and ulcerative 
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Purity and stability of curcumin used in the study. A: HPLC analysis of curcumin was 
performed as described in the Materials and Methods section. No contaminating 
curcuminoids (demetoxycurcumin, or bis-demetoxycurcumin), commonly detected as 
contaminants in commercial curcumin, were detectable in the preparation. B: Mass 
spectrometry (MS) analysis of curcumin. Its melting point, elemental analysis, molecular 
weight by MS, and H NMR were in accord with the structure. C: Chromatographic analysis 
of curcumin stability in the mouse diet did not indicate any degradation over a 24-hour 
period. A slight increase in the amount of extracted curcumin was observed between times 0 
and 9 hours, possibly because of partitioning of hydrophobic curcumin into the lipid phase 
of the diet, which was more accessible to the organic solvents used in the extraction 
procedure.
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A: Survival of TNBS-treated BALB/c and SJL/J mice fed control diet (dotted line) and 2% 
curcumin–supplemented diet (solid line). Dietary curcumin significantly improved the 
survival of colitic BALB/c mice but not SJL/J mice. B: Body weight loss and recovery in 
control and TNBS-treated BALB/c and SJL/J mice fed the control or the 2% curcumin–
supplemented diet. The curcumin diet prevented body weight loss in BALB/c mice but not 
SJL/J mice.
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Histological analysis (H&E staining) of colonic morphology in control and TNBS-treated 
BALB/c and SJL/J mice fed the control or the 2% curcumin–supplemented diet. A–C: 
BALB/c mice; D–F: SJL/J mice. G: Summary of histological damage scoring expressed as 
the sum of the scores from the proximal and distal segments of the mouse colon. Consistent 
with the effects on mortality and body weight loss, curcumin treatment resulted in 
statistically significant improvement of the histology scores of BALB/c mice but not SJL/J 
mice.
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Venn diagram depicting a difference in the colonic gene expression pattern in BALB/c and 
SJL/J mice in response to TNBS. The number of genes/probe sets up- or down-regulated at 
least 1.5-fold (P < 0.05, Student t test) in the BALB/c mice (blue and gray overlap) and the 
SJL/J mice (green and gray overlap) indicated a significantly different response to the same 
haptenizing agent, with a relatively small number of genes dysregulated in both strains.
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A: Genes/probe sets dysregulated by TNBS colitis (≥1.5-fold, P < 0.05) in the BALB/c mice 
(965 genes) or the SJL/J mice (800 genes) were subjected to 1-way ANOVA followed by 
the Student-Newman-Keuls (SNK) post hoc test. Four hundred and sixty-nine genes/probe 
sets in the BALB/c mice and 211 in the SJL/J mice passed ANOVA. Of these, 428 genes 
were normalized by curcumin treatment of the BALB/c mice (SNK, P < 0.05, TNBS versus 
TNBS/curcumin), but only 41 by curcumin treatment of the SJL/J mice. To demonstrate 
dramatic difference in the effect of curcumin in the 2 mouse strains, 428 genes from the 
SNK analysis of the BALB/c mice were plotted with their respective expression values from 
the BALB/c mice (B) and the SJL/J mice (C).
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Gene ontology analysis using the DAVID Functional Annotation Tool (http://
david.abcc.ncifcrf.gov/) of the 116 gene/probe sets (97 nonredundant well-characterized 
genes) whose expression was normalized by curcumin in BALB/c mice but not SJL/J mice 
based on post hoc analyses. Genes categorized based on biological process were grouped 
and ranked (threshold of 4, P < 0.05). Categories were sorted according to the EASE score, 
a modified Fisher exact P value.
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Real-time RT-PCR analysis of colonic expression of TNFα mRNA in BALB/c and SJL/J 
mice. The results were analyzed with TATA box–binding protein as an internal control 
using the ΔΔCt method, with control BALB/c mice (open bar) used as a calibrator. 
Statistical analysis was performed with ANOVA (P < 0.0007) followed by the Fisher PLSD 
post hoc test. Different letters next to bars indicate statistical differences (Fisher PLSD test, 
P < 0.05).
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Effects of low, noncytotoxic concentrations of curcumin on ConA-induced proliferation of 
splenocytes (A,B) or magnetically selected CD4+ lymphocytes (C,D) obtained from naive 
BALB/c (A,C) or SJL/J mice (B,D). Dose-dependent inhibition of splenocyte proliferation 
was only observed in BALB/c mice, whereas the calculated IC50 of curcumin for the 
inhibition of CD4+ cell proliferation was significantly higher in SJL/J mice (P < 0.05; 
Student t test). All data were derived from 5 independent experiments with a minimum of 4 
repetitions per treatment (*statistical difference between control and ConA-treated 
cells; #statistical difference between ConA and ConA+Curcumin treatment groups).
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TABLE 1
Gene Expression Data (Fold Change Compared to Control Group) of the 97 Nonredundant Well-
Characterized Genes Whose Expression Was Normalized by Curcumin in BALB/c Mice and Not in SJL/J 
Mice Based on Post-Hoc Analyses
Gene Description BALB/c SJL/J
TNBS TNBS/Curcumin TNBS TNBS/Curcumin
Acute-phase response
 REG3A Regenerating islet-derived 3 alpha 109.00 6.67 37.70 67.10
 REG3G Regenerating islet-derived 3 gamma 11.50 1.49 1.39 1.48
 SERPINA3 Serine (or cysteine) peptidase inhibitor, clade a, member
 3n
10.60 0.89 3.06 5.51
 REG3D Regenerating islet-derived 3 delta 8.85 1.04 14.30 24.50
Cell adhesion FN1 fibronectin 1
 THBS1 Thrombospondin 1 2.26 1.22 1.74 2.19
 TNC* Tenascin c 2.25 1.08 1.45 2.12
 COL1A2 Procollagen, type I, alpha 2 2.17 0.95 1.68 2.25
 VCAN Versican 2.13 1.23 2.53 3.68
 TGM2 Transglutaminase 2, c polypeptide 2.10 1.23 1.69 2.58
 FBLN2 Fibulin 2 1.97 0.98 1.53 1.79
 COL4A1 Procollagen, type IV, alpha 1 1.96 1.12 2.05 3.62
 COL5A2 Procollagen, type V, alpha 2 1.93 1.12 1.60 1.92
 EMB Embigin 1.74 1.13 2.02 2.86
 COL4A2 Procollagen, type IV, alpha 2 1.74 0.97 1.62 3.15
 ICAM1* Intercellular adhesion molecule 1 (CD54) 1.69 1.10 1.79 2.00
 MADCAM1* Mucosal vascular addressin cell adhesion molecule 1 1.67 1.08 1.40 1.98
 PDPN Podoplanin 1.65 1.12 1.53 2.02
 CD47 cd47 Antigen (rh-related antigen, integrin-associated
 signal transducer)
1.64 1.07 1.28 1.73
 COL5A1 Procollagen, type v, alpha 1 1.64 0.99 1.27 1.39
 Thy Thymus cell antigen 1, theta 1.60 1.12 1.96 2.74
1.59 1.01 1.56 1.93
Defense/immune/inflammatory response, response to biotic stimulus,
 response to wounding
 S100A9 s100 Calcium binding protein a9 (calgranulin b) 62.80 3.09 48.90 101.00
 Chi3l3* Chitinase 3-like 3 44.80 0.94 38.20 76.70
 S100A8 s100 Calcium binding protein a8 (calgranulin a) 41.60 1.48 59.10 137.00
 CXCL2 Chemokine (c-x-c motif) ligand 2 6.41 1.10 31.30 72.70
 IL1B* Interleukin 1 beta 3.56 1.14 11.10 21.30
 PTX3 Pentraxin-related gene, rapidly induced by IL-1 beta 2.98 0.94 3.11 7.16
 LBP* Lipopolysaccharide binding protein 2.69 0.80 1.38 2.06
 IL6* Interleukin 6 2.44 0.89 2.50 6.40
 LILRB3 Leukocyte immunoglobulin-like receptor, subfamily b,
 member 3
2.26 1.06 2.27 5.12
 C3* Complement component 3 2.24 1.10 3.40 6.11
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Gene Description BALB/c SJL/J
TNBS TNBS/Curcumin TNBS TNBS/Curcumin
 FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 2.06 0.86 1.42 2.82
 CEBPB CCAAT/enhancer binding protein (c/ebp), beta 1.95 0.98 1.59 2.68
 C1QB Complement component 1, q subcomponent, B chain 1.90 1.13 1.88 2.16
 C1QB Complement component 1, q subcomponent, B chain 1.90 1.13 1.88 2.16
 C4B Complement component 4b (childo blood group) 1.79 1.08 1.86 2.54
 LCP1 Lymphocyte cytosolic protein 1 (L-plastin) 1.66 0.98 1.61 2.59
 LYZ Lysozyme 1.63 1.05 1.90 3.43
 BCL3 B-cell CLL/lymphoma 3 1.55 0.81 1.23 1.46
 ARHGDIB Rho, GDP dissociation inhibitor (GDI) beta 1.50 1.09 1.60 2.60
 CES3 Carboxylesterase 3 0.45 0.90 0.73 0.73
Transport
 LCN2* Lipocalin 2 63.50 1.74 15.00 39.00
 CLCA6 Chloride channel calcium activated 6 35.00 1.39 1.28 1.45
 Slc20a1 Solute carrier family 20, member 1 (Pit-1) 0.50 1.10 0.68 0.67
 ABCB1 ATP-binding cassette, sub-family B (MDR/TAP),
 member 1A
0.50 1.07 0.80 0.92
 SLC30A10 Solute carrier family 30, member 10 0.37 0.78 0.87 0.79
Response to stress
 PTGS2* Prostaglandin-endoperoxide synthase 2 (COX-2) 3.59 1.20 3.29 7.66
 HSPB7 Heat shock protein family, member 7 (cardiovascular) 1.83 1.10 1.20 1.25
Enzyme linked receptor protein signaling pathway
 LOX Lysyl oxidase 4.06 1.16 3.85 7.95
 IGF1 Insulin-like growth factor 1 (somatomedin C) 2.41 1.22 1.97 2.58
 Sparc Secreted protein, acidic, cysteine-rich (osteonectin) 2.11 1.29 1.78 2.19
 PTPRO Protein tyrosine phosphatase, receptor type, o 1.90 1.19 1.73 2.03
 GRB10 Growth factor receptor-bound protein 10 1.56 1.03 1.89 2.37
Development
 PLA2G2A Phospholipase A2, group IIA (platelets, synovial fluid) 8.48 1.58 1.64 1.67
 TIMP1 TIMP metallopeptidase inhibitor 5.71 1.10 5.53 13.50
 GREM1 Gremlin 1 2.55 0.96 1.87 2.25
 IGFBP4 Insulin-like growth factor binding protein 4 2.32 1.04 1.86 2.65
 CAPG Capping protein (actin filament), gelsolin-like 2.30 1.49 1.43 1.75
 IGFBP5 Insulin-like growth factor binding protein 5 2.15 1.23 1.70 1.92
 RREB1 Ras responsive element binding protein 1 0.50 1.08 0.76 0.73
 PHOX2 Paired-like homeobox 2b 0.33 0.88 0.77 0.57
Nitrogen compound metabolism
 SRM Spermidine synthase 1.53 0.94 0.99 1.33
 GOT1L1 Glutamic-oxaloacetic transaminase 1-like 1 0.50 0.99 1.34 1.52
 MAOA Monoamine oxidase a 0.50 1.11 0.73 0.79
Other
 CTLA2A* Cytotoxic T lymphocyte–associated protein 2 alpha 6.48 1.27 2.64 3.53
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Gene Description BALB/c SJL/J
TNBS TNBS/Curcumin TNBS TNBS/Curcumin
 RETNLB Resistin like beta 4.18 1.55 0.75 0.67
 TRIM15 Tripartite motif-containing 15 3.85 1.26 1.25 1.40
 SLPI Secretory leukocyte peptidase inhibitor 3.31 1.33 2.96 3.36
 RBP1 Retinol binding protein 1, cellular 2.61 1.12 3.49 6.26
 SERPINE2 Serpin peptidase inhibitor, clade E, member 2 2.50 1.46 1.68 2.09
 CSF2RB Colony stimulating factor 2 receptor, beta, low-affinity
 (granulocyte-macrophage)
2.18 0.99 2.57 5.22
 GDA Guanine deaminase 2.18 1.02 1.23 1.27
 FPRL2 Formyl peptide receptor-like 2 2.16 0.96 2.06 5.48
 OSMR Oncostatin M receptor 2.11 1.04 1.46 2.06
 LGMN Legumain 2.03 1.02 1.23 1.43
 PGS1 Phosphatidylglycerophosphate synthase 1 1.96 0.99 1.34 1.54
 FSTL1 Follistatin-like 1 1.88 1.12 1.94 2.54
 BGN Biglycan 1.87 1.24 1.88 2.57
 TYROBP TYRO protein tyrosine kinase binding protein 1.83 1.07 2.09 3.06
 SULF2 Sulfatase 2 1.81 1.04 1.44 1.66
 PLOD2 Procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 1.79 1.10 1.47 2.16
 MSN Moesin 1.74 1.00 1.80 2.42
 ITM2A Integral membrane protein 2A 1.74 1.05 2.09 3.33
 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 1.59 1.12 1.52 2.11
 HEBP2 Heme binding protein 2 1.54 1.12 1.04 1.11
 MMP2 Matrix metallopeptidase 2 1.51 1.03 1.61 2.19
 GGTA1 Glycoprotein galactosyltransferase alpha 1 1.50 0.89 1.44 2.07
 AKAP6 A kinase (PRKA) anchor protein 6 0.62 1.15 1.11 1.41
 ARHGAP24 Rho GTPase activating protein 24 0.50 0.95 1.25 1.57
 METTL7A Methyltransferase like 7A 0.50 1.08 0.83 0.80
 SMPX Small muscle protein, X-linked 0.50 0.89 0.79 0.62
 GSN Gelsolin 0.50 0.87 0.60 0.65
 MRPL47 Mitochondrial ribosomal protein L47 0.50 1.48 0.95 1.32
 NMT2 N-myristoyltransferase 2 0.50 1.44 1.77 2.48
 METTL7A Methyltransferase like 7A 0.50 1.14 0.76 0.73
 UGT2B5 UDP glucuronosyltransferase 2 family, polypeptide B5 0.40 1.25 0.78 0.84
 CES1 Carboxylesterase 1 (monocyte/macrophage Ser esterase 
1)
0.34 1.02 0.70 0.78
Genes were grouped based on their biological process assignment and sorted within groups based on fold-change in TNBS colitis in BALB/c mice. 
Asterisks next to gene symbols indicate genes selected and confirmed by real-time RT-PCR analysis.
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TABLE 2
POSSUM Analysis (http://www.cisreg.ca/oPOSSUM/) of Overrepresented Predicted Transcription Factor–
Binding Sites in the Set of 97 Nonredundant Genes Whose Expression Was Normalized by Curcumin in 










RXR-VDR 7 3 7 3 12.0 0.024
Fos 233 24 346 52 11.9 0.035
Hox 11-CTF1 16 5 16 5 11.6 0.010
cEBP 179 16 262 35 9.5 0.024
SRY 283 26 623 75 9.3 0.089
MEF 2A 96 12 123 18 7.4 0.045
HLF 108 13 121 17 7.3 0.047
SRF 11 3 11 3 7.3 0.060
PPARG-RXRA 8 2 8 2 7.1 0.138
Prrx 2 322 27 916 105 7.0 0.188
FOXD1 159 16 204 25 5.2 0.101
Nkx2-5 383 29 1118 113 5.1 0.379
RELA 113 14 128 16 4.9 0.033
TCF1 33 5 35 5 4.4 0.101
Sox5 317 27 691 70 4.0 0.165
SOX9 211 20 336 35 3.7 0.108
NFKB1 76 9 83 10 3.7 0.101
REL 194 21 269 28 3.5 0.032
TAL1-TCF3 95 12 118 13 3.3 0.042
NFIl3 51 7 57 7 3.2 0.082
From the submitted 97 genes, 71 were included in the analysis focused on 1000 bp upstream of transcription start site and compared to a defined 
genomic region of 1000 randomly selected background genes. TFBS, transcription factor–binding site; background gene hits, number of genes with 
binding site(s) in the 1000-bp set of background genes; target gene hits, number of genes with binding site(s) in the 71 tested genes; background 
TFBS hits, number of binding sites in the 1000-bp set of background genes; target TFBS hits, number of binding sites in the 71 tested genes; Z 
score, measure of the rate of occurrence of a TFBS in the target set of genes compared to the expected rate estimated from the precomputed 
background set; Fisher score, 1-tailed Fisher exact probability comparing the proportion of coexpressed genes containing a particular TFBS to the 
proportion of the background set that contained the site to determine the probability of a nonrandom association between the coexepressed gene set 
and the TFBS of interest.
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